Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

Aug 03, 12:23 PM

The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (Nasdaq: COCP) (“the Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. CFO and co-interim CEO James (Jim) Martin joined Stock Day host Sever Copley.